Several possible studies
Story checked
Trial results show no survival benefit with the use of proton therapy in patients with advanced hepatocellular carcinoma (opens in a new tab)
medicalxpress.com · 2026-10-04
Short answer
Several possible studiesNo clear answer.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
Trial results show no survival benefit with the use of proton therapy in patients with advanced hepatocellular carcinoma
medicalxpress.com · 2026-10-04
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Several studies could be the source of this story.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Open claim evidenceSearch result
Several studies could fit.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Source layer
The paper behind the story
The source record for this check.
The research anchor for the report.
- Points somewhere elsepresented as the new finding
Initial Results of NRG Oncology NRG-GI003: A Phase III Randomized Trial of Protons versus Photons for Hepatocellular Carcinoma (HCC)
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 6Not checkedInitial results of the NRG Oncology NRG-GI003 clinical study comparing proton and photon therapy for patients with advanced hepatocellular carcinoma indicate that proton therapy did not improve the primary objective of overall survival.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 6Not checkedAt the planned interim analysis, the trial was released for reporting after it crossed the futility boundary.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 6Not checkedProton therapy also did not improve the trial's secondary endpoints, including progression-free survival and local progression.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 6Not checkedFewer grade 3 or higher treatment-related adverse events were observed with proton therapy than with photon therapy, but the difference was not statistically significant (11% vs. 24%; p=0.093).View evidenceHide evidence
As stated11% vs. 24%
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 6Not checkedThe phase III trial enrolled 115 eligible patients, stratified them by planned treatment fractions and presence of tumor vascular thrombosis, and randomly assigned them to receive proton therapy or photon therapy.View evidenceHide evidence
As stated115 eligible patients
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 6 of 6Not checkedThe trial was designed for an overall survival hazard ratio favoring protons, and at interim analysis protons did not show an improvement in overall survival compared with photons (HR=1.30, 90% CI 0.83–2.04).View evidenceHide evidence
As statedHR=1.30, 90% CI 0.83–2.04
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Crossref, Europe PMC · 15 candidate papers
Comparison of gantry-less magnetic resonance guided proton therapy with photon therapy for hepatocellular carcinoma patients.
Physics and Imaging in Radiation Oncology · 2026 · PubMed, Crossref
Improved Outcomes Seen With Sorafenib Plus TACE in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis
Default Digital Object Group · 2023 · Crossref
Comparison of proton vs. photon radiotherapy for liver cancer: a meta-analysis.
2026 · Europe PMC
Safety and Efficacy of External Beam Radiation Therapy in Hepatocellular Carcinoma Patients Previously Treated With Yttrium 90 Transarterial Radioembolization.
Advances in Radiation Oncology · 2026 · PubMed
Randomized Trial of Post-Operative Interferon Therapy After Resection of Hepatitis C Virus-Related Hepatocellular Carcinoma and Long-Term Outcome
Therapy for Viral Hepatitis and Prevention of Hepatocellular Carcinoma · 2004 · Crossref
And 10 more candidates considered.